Tang Xiang-Hua, Yu Meng-Ting, Hu Yin, He Ming-Guang, Yang Xiao
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510060, Guangdong Province, China.
Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria 3004, Australia.
Int J Ophthalmol. 2023 Oct 18;16(10):1712-1717. doi: 10.18240/ijo.2023.10.22. eCollection 2023.
To report the myopia-controlling effect of repeated low-level red-light (RLRL) therapy in patients with Stickler syndrome (STL), an inherited collagenic disease typically presenting with early onset myopia.
Three STL children, aged 3, 7, and 11y, received RLRL therapy throughout the follow-up period of 17, 3, and 6mo, respectively after exclusion of fundus anomalies. Data on best-corrected visual acuity (BCVA), intraocular pressure, cycloplegic subjective refraction, ocular biometrics, scanning laser ophthalmoscope, optical coherence tomography, genetic testing, systemic disease history, and family history were recorded.
At the initiation of the RLRL therapy, the spherical equivalent (SE) of 6 eyes from 3 patients ranged from -3.75 to -20.38 D, axial length (AL) were from 23.88 to 30.68 mm, and BCVA were from 0.4 to 1.0 (decimal notation). Myopia progression of all six eyes slowed down after RLRL therapy. AL in five out of the six eyes shortened -0.07 to -0.63 mm. No side effects were observed.
Three cases of STL whose progression of myopic shift and AL elongation are successfully reduced and even reversed after RLRL therapy.
报告重复低强度红光(RLRL)疗法对史-戴综合征(STL)患者近视的控制效果,STL是一种遗传性胶原疾病,通常表现为早发性近视。
3例分别为3岁、7岁和11岁的STL儿童,在排除眼底异常后,分别接受了为期17个月、3个月和6个月的RLRL治疗。记录最佳矫正视力(BCVA)、眼压、睫状肌麻痹主观验光、眼生物测量、扫描激光检眼镜、光学相干断层扫描、基因检测、全身疾病史和家族史等数据。
在开始RLRL治疗时,3例患者6只眼的等效球镜度(SE)范围为-3.75至-20.38 D,眼轴长度(AL)为23.88至30.68 mm,BCVA为0.4至1.0(十进制记数法)。RLRL治疗后,所有6只眼的近视进展均减缓。6只眼中有5只眼的AL缩短了-0.07至-0.63 mm。未观察到副作用。
3例STL患者在RLRL治疗后,近视移位进展和AL延长成功减缓甚至逆转。